While there is substantial cross-talk between the CDKN2A and P53 cell cycle pathways, these tumor suppressors have demonstrated cell cycle–independent roles in the production of and response to reactive oxygen species (ROS). This evidence concerns the gene CDKN2A and neoplasm.